The Influence of Energy of Consciousness Healing Treatment on Low Bioavailable Resveratrol in Male Sprague Dawley Rats
International Journal of Clinical and Developmental Anatomy
Volume 3, Issue 3, May 2017, Pages: 19-25
Received: May 20, 2017; Accepted: Jun. 14, 2017; Published: Jul. 14, 2017
Views 58      Downloads 2
Alice Branton, Trivedi Global, Inc., Henderson, Nevada, USA
Snehasis Jana, Trivedi Science Research Laboratory Pvt. Ltd., Bhopal, Madhya Pradesh, India
Article Tools
Follow on us
Resveratrol is a natural dietary antioxidant polyphenol that believed to be effective in improving overall health. The biological activity of resveratrol is limited by its poor absorption and first-pass metabolism that lead to have very low plasma concentrations following oral administration. Therefore, the present study was performed to determine the effects of The Trivedi Effect®-Energy of Consciousness Healing Treatment by a renowned Biofield Energy Healer, Alice Branton on resveratrol and rats through the measurement of plasma concentrations after oral administration of resveratrol. The test item, resveratrol was divided into two parts. One part was denoted as the control, while the other part was defined as the Biofield Energy Treated sample. Additionally, one group of animals also received Biofield Energy Treatment under similar conditions. Resveratrol oral formulations were administrated by oral gavage at a dose of 150 mg/kg in groups viz. G1 (untreated resveratrol), G2 (Biofield Treated resveratrol) and G3 (Biofield Treated animals received untreated resveratrol) group. The results showed that resveratrol had a very low oral plasma exposure of 91.71 ng/mL in control group. The Biofield Treatment significantly enhanced the relative oral exposure (AUC0–t) of resveratrol by 23.35% in G2 group compared to the control group. The Biofield Treatment also improved plasma peak concentration (Cmax) of resveratrol by 125% and 28.5% in G2 and G3 groups, respectively compared with the control group. Plasma concentrations of resveratrol in G1 was declined with a rapid elimination half-life (T1/2, 1.48 hours), followed by sudden increases in plasma concentrations 12 to 24 hours after the test item administration. These plasma concentrations resulted in a significant prolongation of the terminal elimination half-life of resveratrol. The oral elimination T1/2 of resveratrol in G2 and G3 were 4.67 and 9.0 hours, respectively as compared to the G1. The apparent oral plasma clearance of resveratrol decreased significantly by 54%, and 17.5% in G2 group and G3 group, respectively as compared to the control group. The mean residence time (MRTlast) of resveratrol significantly increased in G2 group (6.45 hours) and G3 group (7.70 hours), as compared to the control group. These data demonstrates greater bioavailability and total plasma level of resveratrol in rats which might be translated into better in vivo biological activity. Hence, The Trivedi Effect®-Energy of Consciousness Healing Treatment could be considered as an innovative strategy which opens new avenues to overcome poorly absorbed nutraceuticals/pharmaceuticals and can also improve the therapeutic performance of orally active molecules.
Resveratrol, Biofield Energy Healing Treatment, Pharmacokinetics, Bioavailability, LC-MS/MS, Rat
To cite this article
Alice Branton, Snehasis Jana, The Influence of Energy of Consciousness Healing Treatment on Low Bioavailable Resveratrol in Male Sprague Dawley Rats, International Journal of Clinical and Developmental Anatomy. Vol. 3, No. 3, 2017, pp. 19-25. doi: 10.11648/j.ijcda.20170303.11
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Langcake P (1981) Disease resistance of Vitis spp. and the production of the stress metabolites resveratrol, epsilon-viniferin, alpha-viniferin and pterostilbene. Physiol Plant Pathol 18: 213–226.
Gambini J, López-Grueso R, Olaso-González G, Inglés M, Abdelazid K, et al. (2013) Resveratrol: distribution, properties and perspectives. Rev Esp Geriatr Gerontol 48: 79-88.
Kraft TE, Parisotto D, Schempp C, Efferth T (2009) Fighting cancer with red wine? Molecular mechanisms of resveratrol. Crit Rev Food Sci Nutr 49: 782-799.
Renaud S, de Lorgeril M (1992) Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339: 1523-1526.
Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes. Science 275: 218-220.
Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, et al. (2004) Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res 24: 2783-2840.
Delmas D, Aires V, Limagne E, Dutartre P, Mazué F, Ghiringhelli F, Latruffe N (2011) Transport, stability, and biological activity of resveratrol. Ann N Y Acad Sci 1215: 48-59.
Marques FZ, Markus MA, Morris BJ (2009) Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell Biol 41: 2125-2128.
Paul S, Rimando AM, Lee HJ, Ji Y, Reddy BS, Suh N (2009) Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells. Cancer Prev Res 2: 650-657.
Pervaiz S, Holme AL (2009) Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 11: 2851-2897.
Bishayee A (2009) Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res 2: 409-418.
De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM (2000) Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica 30: 609-617.
Rimando AM, Suh N (2008) Biological/chemopreventive activity of stilbenes and their effect on colon cancer. Planta Med 74: 1635-1643.
Walle T (2011) Bioavailability of resveratrol. Ann N Y Acad Sci 1215: 9-15.
Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas A, Piccirilli G, Brown K, Steward W, Gescher AJ, Brenner DE (2010) Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis. Cancer Res 70: 9003-9011.
Kansara H, Panola R, Mishra A (2015) Techniques used to Enhance Bioavailability of BCS Class II Drugs: A Review. Int J Drug Dev & Res 7: 82-93.
Rubik B, Muehsam D, Hammerschlag R, Jain S (2015) Biofield science and healing: history, terminology, and concepts. Glob Adv Health Med 4: 8-14.
Barnes PM, Bloom B, Nahin RL (2008) Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 12: 1-23.
Trivedi MK, Tallapragada RM (2008) A transcendental to changing metal powder characteristics. Met Powder Rep 63: 22-28, 31.
Trivedi MK, Nayak G, Patil S, Tallapragada RM, Latiyal O (2015) Studies of the atomic and crystalline characteristics of ceramic oxide nano powders after bio field treatment. Ind Eng Manage 4: 161.
Trivedi MK, Nayak G, Patil S, Tallapragada RM, Latiyal O, Jana S (2015) Effect of Biofield energy treatment on physical and structural properties of calcium carbide and praseodymium oxide. International Journal of Materials Science and Applications 4: 390-395.
Trivedi MK, Tallapragada RM, Branton A, Trivedi D, Nayak G, Latiyal O, Jana S (2015) Characterization of physical, thermal and structural properties of chromium (VI) oxide powder: Impact of biofield treatment. J Powder Metall Min 4: 128.
Patil SA, Nayak GB, Barve SS, Tembe RP, Khan RR (2012) Impact of biofield treatment on growth and anatomical characteristics of Pogostemon cablin (Benth.). Biotechnology 11: 154-162.
Nayak G, Altekar N (2015) Effect of biofield treatment on plant growth and adaptation. J Environ Health Sci 1: 1-9.
Trivedi MK, Patil S, Shettigar H, Gangwar M, Jana S (2015) Antimicrobial sensitivity pattern of Pseudomonas fluorescens after biofield treatment. J Infect Dis Ther 3: 222.
Trivedi MK, Patil S, Shettigar H, Bairwa K, Jana S (2015) Phenotypic and biotypic characterization of Klebsiella oxytoca: An impact of biofield treatment. J Microb Biochem Technol 7: 203-206.
Trivedi MK, Patil S, Shettigar H, Gangwar M, Jana S (2015) An effect of biofield treatment on multidrug-resistant Burkholderia cepacia: A multihost pathogen. J Trop Dis 3: 167.
Trivedi MK, Branton A, Trivedi D, Nayak G, Balmer AJ, Anagnos D, Kinney JP, Holling JM, Balmer JA, Duprey-Reed LA, Parulkar VR, Panda P, Sethi KK, Jana S (2017) Evaluation of the Energy of Consciousness Healing Treated Withania Somnifera (Ashwagandha) Root Extract Using LC-MS, GC-MS, and NMR Spectroscopy, American Journal of Biomedical and Life Sciences 5: 16-25.
Trivedi MK, Branton A, Trivedi D, Nayak G, Balmer AJ, Anagnos D, Kinney JP, Holling JM, Balmer JA, Duprey-Reed LA, Parulkar VR, Panda P, Sethi KK, Jana S (2017) Evaluation of Physicochemical, Spectral, Thermal and Behavioral Properties of the Biofield Energy Healing Treated Sodium Selenate, Science Journal of Chemistry 5: 12-22.
Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC, Jana S (2015) Effect of biofield treated energized water on the growth and health status in chicken (Gallus gallus domesticus). Poult Fish Wildl Sci 3: 140.
Trivedi MK, Mohan TRR (2016) Biofield energy signals, energy transmission and neutrinos. American Journal of Modern Physics 5: 172-176.
Brisdelli F, D’Andrea G, Bozzi A (2009) Resveratrol: a natural polyphenol with multiple chemopreventive properties (Review). Curr Drug Metab 10: 530-546.
Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL (2009) Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys 486: 95-102.
Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, Kim AL (2007) Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 224: 274-283.
Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506.
Jeandet P, Douillet-Breuil AC, Bessis R, Debord S, Sbaghi M, Adrian M (2002) Phytoalexins from the vitaceae: biosynthesis, phytoalexin gene expression in transgenic plants, antifungal activity and metabolism. J Agri Food Chem 50: 2731-2741.
Adrian M, Jeandet P, Veneau J, Weston LA, Bessis R (1997) Biological activity of resveratrol, a stilbenic compound from grapevines, against Botrytis cinerea, the causal agent for gray mold. J of Chem Ecology 23: 1689-1702.
Soleas GJ, Diamandis EP, Goldberg DM (1997) Resveratrol: a molecule whose time has come? And gone?” Clinical Biochem 30: 91-113.
Siemann EH, Creasy LL (1992) Concentration of the phytoalexin resveratrol in wine. Am J of Enology and Viticulture. 43: 49-52.
Das DK (2006) Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interv. 6: 36-47.
Dominique Bonnefont-Rousselot D (2016) Resveratrol and Cardiovascular Diseases. Nutrients 8: 250.
Li H, Xia N, Förstermann U (2012) Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide 26: 102-110.
Jing YH, Chen KH, Yang SH, Kuo PC, Chen JK (2010) Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: role of AGE-RAGE signalling. Diabetes Metab Res Rev 26: 212222.
Das S, Lin HS, Ho PC, Ng KY (2008) The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res 25: 2593-2600.
Nunes T, Almeida L, Rocha JF, Falcão A, Fernandes-Lopes C, Loureiro AI, Wright L, Vaz-da-Silva M, Soares-da-Silva P. (2009) Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J Clin Pharmacol 49: 1477-1482.
Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP (2002) Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 302: 369-373.
Science Publishing Group
NEW YORK, NY 10018
Tel: (001)347-688-8931